The decision to halt LVA surgeries reflects a deeper reckoning with medical ethics, desperation, and the high cost of uncertain hope.
In a decisive move, China’s National Health Commission has ordered all hospitals and medical institutions to immediately stop performing lymphatic-venous anastomosis (LVA) surgery on patients with Alzheimer’s disease. The procedure, which links lymphatic vessels to nearby veins to accelerate the removal of harmful brain proteins, had been gaining ground rapidly—performed at nearly 400 hospitals in just four years. But the government now says there’s simply not enough evidence to prove it works.
The ban has sparked a heated national debate, drawing in scientists, desperate families, and healthcare reform advocates, all grappling with the same core question: When does hope cross the line into harm?
A Treatment Built on Fragile Foundations
Alzheimer’s disease remains one of the world’s most devastating neurological disorders. It robs individuals of memory, independence, and ultimately identity. In a nation like China—home to more than 10 million people with dementia—the hunger for a cure is urgent and deeply personal. That urgency likely explains why LVA surgery took off so quickly, even in the absence of rigorous clinical trials.
Promoted as a breakthrough by some doctors on Chinese social media, the surgery was touted as being effective in up to 80% of patients. But those claims were largely anecdotal and lacked peer-reviewed validation. While some patients reportedly showed signs of improvement—recognizing loved ones, becoming more self-reliant—experts now warn that these cases may be outliers, misattributions, or the result of placebo effects.
Dr. Fan Dongsheng, a neurology professor at Peking University Third Hospital, called the clinical enthusiasm “premature.” In an interview with South China Morning Post, he noted that the procedure’s scientific mechanism remains poorly understood, and that claimed improvements weren’t measured using accepted diagnostic tools.
Desperation or Exploitation?
Behind every Alzheimer’s diagnosis is a family in crisis. For many, the decision to try LVA surgery came not from belief in the science, but from exhaustion and desperation. One user on Chinese social media shared that her family agreed to the procedure for her father “because we had no other choice.” Another said his father, treated in March, is now significantly improved and can care for himself.
It’s this tension—between clinical caution and human need—that lies at the heart of China’s decision. While the Health Commission acknowledged the procedure’s growing popularity, it concluded that “insufficient evidence” made continued use unsafe and potentially unethical. Hospitals, the directive emphasized, must prioritize patient well-being over unproven therapies, and families must be protected from being misled or overcharged.
Still, critics argue that the decision feels abrupt and may deny patients even the small possibility of improvement. Others fear that banning the surgery outright will push desperate families toward unregulated or underground clinics.
Medical Hype, Unchecked
The rise of LVA surgery in China is also a story of unchecked medical hype. Introduced in 2021 by a private hospital in Hangzhou, the procedure spread to nearly every province by mid-2025. Some hospitals reportedly charged steep fees despite lacking proper ethical approval or post-operative support systems.
This kind of rapid proliferation exposes gaps in China’s regulatory system—gaps that mirror global challenges in balancing medical innovation with patient safety. It also raises the uncomfortable question: How many patients were sold hope without science?
A Necessary Pause or a Missed Opportunity?
The National Health Commission hasn’t shut the door completely. The new guidelines leave room for future clinical trials—but only under strict ethical review, with full transparency, and once preclinical evidence supports its use. That’s a high bar to clear, and likely years away.
Still, this moment marks an inflection point in the fight against Alzheimer’s in China and beyond. It challenges healthcare systems to ask harder questions about experimental treatments: not just whether they can help, but whether the evidence proves they do—and whether vulnerable families can distinguish the two.
The Broader Alzheimer’s Crisis
Ultimately, the story of LVA surgery is one chapter in the broader global crisis around Alzheimer’s care. With no cure in sight, millions of families are left chasing experimental treatments, herbal remedies, or risky surgeries. The financial, emotional, and moral cost of that pursuit often goes uncounted.
In halting LVA surgeries, China may be taking a stand not just against one procedure, but against a system too quick to monetize fragile hope.
Until science catches up with need, the Alzheimer’s crisis will continue to test not just medicine’s limits—but society’s ethics.